Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

Inclusion Criteria:

* Patients must be HLA-A2 positive at one allele
* Patients with CML in chronic phase or early accelerated phase, who are not eligible for BMT or interferon, or have failed standard therapy, or have relapsed after BMT
* Patients with MDS (FAB subtypes RAEB, and RAEBt) or AML in second or subsequent remission, or AML with a smoldering presentation and who are not candidates for chemotherapy, and who are believed to have a life expectancy of at least 9 weeks
* ECOG performance status \< 3
* Life expectancy is not severely limited by concomitant illness
* Serum bilirubin \< 3 mg/dl
* Serum creatinine \< 2 mg/dl
* ALT \< 3 x the upper limit of normal
* No serologic antibody against proteinase 3
* No known history of Wegener's granulomatosis or other vasculitis
* FEV, FVC, and DLCO \> 50% of predicted, and no symptomatic pulmonary disease
* Not pregnant; all female patients will have a serum pregnancy test, and only those that test negative will be allowed on study
* HIV negative
* No known allergic reaction to Montanide ISA 51 or Montanide ISA 51 VG adjuvant
* No active uncontrolled infection
* Patient or representative able to understand the study and consent
* Patient is not receiving steroids, cyclosporine, or FK-506 for at least 1 month prior to study entry and during study period
* No concomitant use of interferon or chemotherapy during study period other than hydroxyurea to control cell counts
* Patients who relapsed within one year of completing the initial vaccination could be retreated with up to 6 additional vaccinations if they remain eligible for treatment according to the original criteria